Single-center experiences have shown that intensified treatments with autologous transplantation are a promising therapeutic strategy for patients with high-risk follicle-center lymphoma (FCL) at diagnosis, whereas data from prospective multicenter trials are still lacking. This paper describes the results of a prospective multicenter study of an intensified purging-free high-dose sequential (i-HDS) chemotherapy schedule with peripheral blood progenitor cell (PBPC) autografting. The main feature of this program is harvesting stem cells after intensified chemotherapeutic debulking, with no ex vivo manipulation of PBPCs. Ninety-two previously untreated patients aged 60 or younger with advanced-stage FCL were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. i-HDS proved feasible with limited toxicity (87% patients completed the planned treatment schedule). i-HDS led to a complete remission rate of 88%. The projected overall survival and disease-free survival (DFS) were, respectively, 84% and 67% at 4 years. Centralized molecular analysis showed that polymerase chain reaction-negative harvests could be collected in 47% of cases. Following autograft, 65% of molecularly evaluable patients achieved clinical and molecular remission. The projected DFS at 4 years of this subgroup is 85%. This result emphasizes the importance of achieving maximal tumor reduction in these patients. In conclusion, our data show that highly effective intensified treatments can now be routinely offered to young patients with poor-risk FCL even at small institutions, with no need for sophisticated and expensive cell manipulation procedures.

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high- dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) / M., Ladetto; P., Corradini; S., Vallet; F., Benedetti; U., Vitolo; Martelli, Maurizio; M., Brugiatelli; P., Coser; A., Perrotti; I., Majolino; G., Fioritoni; S., Morandi; M., Musso; R., Zambello; T., Chisesi; N., DI RENZO; P., Vivaldi; A., DE CRESCENZO; A., Gallamini; F., Salvi; G., Santini; C., Boccomini; M., Sorio; M., Astolfi; D., Drandi; A. PILERI, C. TARELLA. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 100:5(2002), pp. 1559-1565. [10.1182/blood-2002-02-0621]

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high- dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

MARTELLI, Maurizio;
2002

Abstract

Single-center experiences have shown that intensified treatments with autologous transplantation are a promising therapeutic strategy for patients with high-risk follicle-center lymphoma (FCL) at diagnosis, whereas data from prospective multicenter trials are still lacking. This paper describes the results of a prospective multicenter study of an intensified purging-free high-dose sequential (i-HDS) chemotherapy schedule with peripheral blood progenitor cell (PBPC) autografting. The main feature of this program is harvesting stem cells after intensified chemotherapeutic debulking, with no ex vivo manipulation of PBPCs. Ninety-two previously untreated patients aged 60 or younger with advanced-stage FCL were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. i-HDS proved feasible with limited toxicity (87% patients completed the planned treatment schedule). i-HDS led to a complete remission rate of 88%. The projected overall survival and disease-free survival (DFS) were, respectively, 84% and 67% at 4 years. Centralized molecular analysis showed that polymerase chain reaction-negative harvests could be collected in 47% of cases. Following autograft, 65% of molecularly evaluable patients achieved clinical and molecular remission. The projected DFS at 4 years of this subgroup is 85%. This result emphasizes the importance of achieving maximal tumor reduction in these patients. In conclusion, our data show that highly effective intensified treatments can now be routinely offered to young patients with poor-risk FCL even at small institutions, with no need for sophisticated and expensive cell manipulation procedures.
2002
AUTOLOGOUS BONE-MARROW, NON-HODGKINS-LYMPHOMA, B-CELL LYMPHOMA, POLYMERASE-CHAIN-REACTION, MINIMAL RESIDUAL DISEASE, LOW-GRADE LYMPHOMA, TERM FOLLOW-UP, MULTIPLE-MYELOMA, BCL-2 TRANSLOCATION, INDOLENT LYMPHOMA
01 Pubblicazione su rivista::01a Articolo in rivista
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high- dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) / M., Ladetto; P., Corradini; S., Vallet; F., Benedetti; U., Vitolo; Martelli, Maurizio; M., Brugiatelli; P., Coser; A., Perrotti; I., Majolino; G., Fioritoni; S., Morandi; M., Musso; R., Zambello; T., Chisesi; N., DI RENZO; P., Vivaldi; A., DE CRESCENZO; A., Gallamini; F., Salvi; G., Santini; C., Boccomini; M., Sorio; M., Astolfi; D., Drandi; A. PILERI, C. TARELLA. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 100:5(2002), pp. 1559-1565. [10.1182/blood-2002-02-0621]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/116912
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 103
  • ???jsp.display-item.citation.isi??? 80
social impact